Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elowen-2 enpatoran study in cutaneous lupus
PACTR202607871198123Phase 3Not yet recruiting
- Sponsor
- Merck KGaA
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing Enpatoran with Placebo (2 arms). Primary endpoint: CLASI 70 at Week 24. Planned start May 2026; status: not yet recruiting.
02
Drugs
enpatoran
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on PACTR202607871198123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202607871198123.